Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

BACKGROUND: Alectinib, a highly selective, central nervous system (CNS)-active anaplastic lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve and crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC). This phase 2 study evaluated the safety an...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet Oncol
Главные авторы: Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ignatius Ou, Sai-Hong
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
https://ncbi.nlm.nih.gov/pubmed/26708155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00488-X
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы